STXBP1 and Encephalopathy: Refractory epilepsy is a prominent feature of STXBP1-encephalopathy, and there is no standard treatment strategy.[19] Our study found that LEV had a good therapeutic effect: 4 of 17 patients (23.5%) who used LEV achieved seizure freedom, which is higher than the efficacy reported in previous studies (10–15%).[20,21] This suggests that LEV may be a 1st-line drug for STXBP1-encephalopathy.